정밀 면역종양학 시장 : 규모, 점유율, 성장 분석, 암 유형별, 치료 유형별, 바이오마커별, 최종 용도별, 지역별 - 산업 예측(2025-2032년)
Precision Immuno-Oncology Market Size, Share, Growth Analysis, By Cancer Type (Lung Cancer, Breast Cancer), By Treatment Type (Checkpoint Inhibitors, Car T Cell Therapy), By Biomarker, By End Use, By Region - Industry Forecast 2025-2032
상품코드:1623737
리서치사:SkyQuest
발행일:2024년 12월
페이지 정보:영문 157 Pages
라이선스 & 가격 (부가세 별도)
한글목차
세계의 정밀 면역종양학 시장 규모는 2023년에 606억 5,000만 달러로 평가되었고, 2024년 672억 달러에서 2032년에는 1,526억 5,000만 달러로 성장해 예측 기간(2025-2032년) CAGR은 10.8%를 나타낼 전망입니다.
정밀 면역종양학은 환자의 유전자 프로파일, 종양특성, 면역반응을 고려한 맞춤형 치료에 초점을 맞춘 암 치료의 선구적 접근으로서 급속히 보급되고 있습니다. 이 맞춤형 치료는 치료효과를 높일 뿐만 아니라 기존의 치료법에 비해 부작용을 최소화하고 장기적인 관해에 대한 희망을 가져옵니다. 임상시험은 특히 치료 저항성 암 환자에서 유망한 결과를 나타내며 환자의 반응이 뚜렷한 것으로 나타났습니다. 이 분야에서는 제약 회사가 정밀 면역종양학의 변화 가능성을 인식함에 따라 많은 투자가 이루어지고 있으며, 암 치료의 진화에 있어서 중요한 이정표가 되어 시장에서의 유망한 장래성을 돋보이고 있습니다.
목차
서문
조사의 목적
조사 범위
정의
조사 방법
정보 조달
2차 데이터와 1차 데이터의 방법
시장 규모 예측
시장의 전제조건과 제한
주요 요약
세계 시장 전망
공급과 수요 동향 분석
부문별 기회 분석
시장 역학과 전망
시장 개요
시장 규모
시장 역학
성장 촉진요인과 기회
성장 억제요인과 과제
Porter's Five Forces 분석
주요 시장 인사이트
중요 성공 요인
경쟁도
주요 투자 기회
시장 생태계
시장의 매력 지수(2024년)
PESTEL 분석
거시경제지표
밸류체인 분석
가격 분석
기술 분석
특허 분석
파이프라인 제품 분석
사례 연구 분석
세계의 정밀 면역종양학 시장 규모 : 암 유형별
시장 개요
폐암
유방암
전립선암
악성 흑색종
기타
세계의 정밀 면역종양학 시장 규모 : 치료 유형별
시장 개요
체크포인트 억제제
CAR T 세포 요법
암 백신
기타
세계의 정밀 면역종양학 시장 규모 : 바이오마커별
시장 개요
PD-L1
BRCA
KRAS
EGFR
기타
세계의 정밀 면역종양학 시장 규모 : 최종 용도별
시장 개요
병원
클리닉
연구기관
기타
세계의 정밀 면역종양학 시장 규모 : 지역별
북미
미국
캐나다
유럽
독일
스페인
프랑스
영국
이탈리아
기타 유럽
아시아태평양
중국
인도
일본
한국
기타 아시아태평양
라틴아메리카
브라질
기타 라틴아메리카
중동 및 아프리카
GCC 국가
남아프리카
기타 중동 및 아프리카
경쟁 정보
상위 5개사 비교
주요 기업의 시장 포지셔닝(2024년)
주요 시장 기업이 채용한 전략
시장의 최근 동향
기업의 시장 점유율 분석(2024년)
주요 기업의 기업 프로파일
기업 개요
제품 포트폴리오 분석
부문별 점유율 분석
수익의 전년대비 비교(2022-2024)
주요 기업 프로파일
Adaptimmune Therapeutics plc(UK)
Agenus Inc.(US)
Amgen Inc.(US)
AstraZeneca plc(UK)
Bristol Myers Squibb Company(US)
Celgene Corporation(US)
Eli Lilly and Company(US)
F.Hoffmann-La Roche Ltd.(Switzerland)
Gilead Sciences, Inc.(US)
GlaxoSmithKline plc(UK)
Iovance Biotherapeutics, Inc.(US)
Juno Therapeutics, Inc.(US)
Kite Pharma, Inc.(US)
Merck&Co., Inc.(US)
Neon Therapeutics, Inc.(US)
Novartis AG(Switzerland)
Pfizer Inc.(US)
Sanofi SA(France)
Seattle Genetics, Inc.(US)
Takeda Pharmaceutical Company Limited(Japan)
결론과 권장사항
KTH
영문 목차
영문목차
Global Precision Immuno-Oncology Market size was valued at USD 60.65 billion in 2023 and is poised to grow from USD 67.20 billion in 2024 to USD 152.65 billion by 2032, growing at a CAGR of 10.8% during the forecast period (2025-2032).
Precision immuno-oncology is swiftly gaining traction as a pioneering approach in cancer treatment, focusing on tailored therapies that consider patients' genetic profiles, tumor characteristics, and immune responses. This personalized strategy not only enhances treatment efficacy but also minimizes side effects compared to conventional therapies, offering hope for long-term remissions. Advanced diagnostics play a crucial role in identifying unique genetic mutations and proteins on cancer cells, enabling targeted interventions. Clinical trials have demonstrated encouraging results, particularly in patients with treatment-resistant cancers, showcasing remarkable patient responses. The sector is witnessing substantial investment as pharmaceutical companies recognize the transformative potential of precision immuno-oncology, marking a significant milestone in the evolution of cancer care and highlighting its promising future in the market.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Precision Immuno-Oncology market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Precision Immuno-Oncology Market Segmental Analysis
Global Precision Immuno-Oncology Market is segmented by cancer type, treatment type, biomarker, end use and region. Based on cancer type, the market is segmented into lung cancer, breast cancer, prostate cancer, melanoma and others. Based on treatment type, the market is segmented into checkpoint inhibitors, Car T Cell Therapy, cancer vaccines and others. Based on biomarker, the market is segmented into PD-L1, BRCA, KRAS, EGFR and others. Based on end use, the market is segmented into hospital, clinics, research institutes and others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Precision Immuno-Oncology Market
The Global Precision Immuno-Oncology market is witnessing significant growth driven by the rising incidence of cancer worldwide. As cancer remains a pressing health issue, the need for advanced treatment options is becoming increasingly urgent. Traditional therapies like chemotherapy and radiation often have severe limitations and side effects, leading to a push for more innovative solutions. Precision immuno-oncology stands out by harnessing the body's immune system to combat cancer effectively. This tailored approach enables the development of targeted therapies based on individual genetic profiles, tumor characteristics, and immune responses, potentially enhancing treatment efficacy while minimizing adverse effects, thus propelling market demand.
Restraints in the Global Precision Immuno-Oncology Market
The Global Precision Immuno-Oncology market faces significant challenges primarily due to the high costs associated with these advanced therapies. Unlike traditional cancer treatments, precision immuno-oncology offers a personalized approach, which inherently involves complex and expensive methodologies. This heightened expense can restrict patient access, particularly for those in developing nations where healthcare resources are scarce. Factors such as exorbitant research and development expenditures, the requirement for specialized equipment, and the processes involved in biomarker testing further escalate costs. The unique treatment plans tailored for individual patients add another layer of expense, creating disparities in access to effective cancer care, especially for individuals from low- and middle-income regions, thereby exacerbating existing inequities in cancer treatment and outcomes.
Market Trends of the Global Precision Immuno-Oncology Market
The Global Precision Immuno-Oncology market is witnessing significant growth driven by the increasing adoption of combination therapies that integrate immunotherapy with traditional treatments like chemotherapy and radiation. This trend is rooted in the rising awareness of the enhanced treatment efficacy and the potential to combat drug resistance inherent in singular therapies. As research continues to yield promising results-especially in complex cancers such as lung cancer and melanoma-clinicians are increasingly leveraging these multi-faceted treatment approaches to improve patient outcomes. Furthermore, advancements in biomarker identification and personalized medicine are expected to further propel market expansion, catering to a more tailored cancer treatment landscape.
Table of Contents
Introduction
Objectives of the Study
Scope of the Report
Definitions
Research Methodology
Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations
Executive Summary
Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis
Market Dynamics & Outlook
Market Overview
Market Size
Market Dynamics
Drivers & Opportunities
Restraints & Challenges
Porters Analysis
Competitive rivalry
Threat of substitute
Bargaining power of buyers
Threat of new entrants
Bargaining power of suppliers
Key Market Insights
Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2024
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Technology Analysis
Patent Analysis
Pipeline Product Analysis
Case Study Analysis
Global Precision Immuno-Oncology Market Size by Cancer Type & CAGR (2025-2032)
Market Overview
Lung Cancer
Breast Cancer
Prostate Cancer
Melanoma
Others
Global Precision Immuno-Oncology Market Size by Treatment Type & CAGR (2025-2032)
Market Overview
Checkpoint Inhibitors
Car T Cell Therapy
Cancer Vaccines
Others
Global Precision Immuno-Oncology Market Size by Biomarker & CAGR (2025-2032)
Market Overview
PD-L1
BRCA
KRAS
EGFR
Others
Global Precision Immuno-Oncology Market Size by End Use & CAGR (2025-2032)
Market Overview
Hospital
Clinics
Research Institutes
Others
Global Precision Immuno-Oncology Market Size & CAGR (2025-2032)
North America (Cancer Type, Treatment Type, Biomarker, End Use)
US
Canada
Europe (Cancer Type, Treatment Type, Biomarker, End Use)
Germany
Spain
France
UK
Italy
Rest of Europe
Asia Pacific (Cancer Type, Treatment Type, Biomarker, End Use)
China
India
Japan
South Korea
Rest of Asia-Pacific
Latin America (Cancer Type, Treatment Type, Biomarker, End Use)
Brazil
Rest of Latin America
Middle East & Africa (Cancer Type, Treatment Type, Biomarker, End Use)
